Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

The global RSV diagnostics market was valued at USD 1028.55 Million in 2024, driven by growing awareness of the severity and impact of respiratory syncytial virus (RSV) infections across the globe. The market is anticipated to grow at a CAGR of 10.20% during the forecast period of 2025-2034, with the values likely to reach USD 2716.70 Million by 2034.

Key Market Trends and Insights

  • Chromatographic immunoassays led the market by product type, holding a share of over 27% in the historical period.
  • Hospitals dominated the market by end user, accounting for over 40% of the global share in the historical period.
  • Rapid antigen detection testing is expected to continue leading by method, supported by its proven effectiveness, fast turnaround time, and growing preference in pediatric and geriatric diagnostic care environments during the forecast period.

Market Size and Forecast

  • Market Size (2024): USD 1028.55 Million 
  • Projected Market Size (2034): USD 2716.70 Million
  • CAGR (2025-2034): 10.20%  

2024

Base Year

2018-2024

Historical Period

2025-2034

Forecast Period

  • Rising global RSV prevalence, especially among infants and the elderly, continues to drive demand for fast, reliable diagnostic solutions.

  • Innovative newborn testing solutions like Thermo Fisher’s RSV Combo Kit are boosting early detection rates and market penetration across pediatric segments.

  • The expansion of high-throughput multiplex systems, such as Roche's cobas LIAT and Hologic's Fusion Assay, is enhancing diagnostic efficiency globally.

Compound Annual Growth Rate

10.2%

Value in USD Million

2025-2034


RSV Diagnostics Market Outlook

*this image is indicative*

RSV Diagnostics Market Overview

Respiratory syncytial virus (RSV) continues to be a leading cause of acute lower respiratory infections globally, with an estimated 33 million infections, 3.6 million hospitalizations, and 100,000 deaths annually in children under five, as reported by the National Institutes of Health (NIH).  In the United States alone, the CDC estimates 58,000-80,000 RSV-related hospitalizations among children and up to 160,000 hospitalizations in adults aged 65+ each year, with 6,000–10,000 resulting deaths in the older population. These alarming figures underscore the urgency of early and reliable diagnostic solutions.  The market is anticipated to grow at a CAGR of 10.20% during the forecast period of 2025-2034.

RSV Diagnostics Market Growth Drivers

Newborn Testing Innovations to Fuel Market Growth

In March  2025, Thermo Fisher Scientific introduced its TaqPath RSV Combo Kit, cleared for use in neonates and pediatric populations. This multiplex RT-PCR test can simultaneously detect RSV, influenza A and B in under two hours. The advancement allows early intervention among the most vulnerable age groups, addressing pediatric RSV hospitalization rates. Such innovations contribute significantly to market expansion by enabling accurate, early detection and reducing disease progression in high-risk newborn populations.

RSV Diagnostics Market Trends

The market is witnessing trends like rising adoption of point of care testing, enhancements in molecular quality control to boost efficiency, innovations in diagnostics to provide better solutions to the patients.

Advancements in Multiplex and High-Throughput Testing Drive Market Growth

The market is witnessing accelerated expansion due to innovations in high-throughput and multiplex testing platforms. For instance, in June  2024, Roche’s cobas® LIAT system received EUA for a 20-minute test detecting RSV, COVID-19, and influenza from a single nasal swab. Hologic’s Panther Fusion Assay, approved in May 2023, enables scalable RSV detection in centralized labs. These rapid and integrated technologies improve diagnostic efficiency, enhance patient triaging, and reduce time-to-treatment across clinical and public health settings.

Preference for Point-of-Care Advancements to Accelerate RSV Diagnostic Market Growth

In May  2025, SEKISUI Diagnostics launched the OSOM® RSV Test, a CLIA-waived rapid immunochromatographic assay that detects RSV nucleoprotein antigens in just 15 minutes. Designed for broader demographic coverage, it is approved for children aged 6 months to 6 years and adults aged 60 and older. This innovation enhances rapid diagnostic capabilities in professional healthcare settings, particularly for high-risk groups, which supports faster treatment decisions and improves clinical outcomes.

Advancements in Molecular Quality Controls to Fuel RSV Diagnostics Market Demand

In May  2025, Bio-Rad Laboratories received the EU quality management systems certificate under IVDR regulation (EU) 2017/746, enabling CE-IVDR marking of 40 Exact Diagnostics infectious disease molecular quality controls. Although these initially focus on pathogens such as HPV, CT/NG, and SARS-CoV-2, the underlying technological and regulatory progress significantly benefits the broader molecular diagnostics market, including RSV. These quality controls simulate patient specimens, enhancing test accuracy and reliability, key factors in RSV diagnostics. As regulatory frameworks evolve, diagnostic companies are incentivized to enhance test performance across all infectious diseases, RSV included.

Adoption of Human Challenge Models to Impact the RSV Diagnostics Market Size Positively 

In September  2024, UK-based hVIVO advanced its human disease modeling platform to accelerate respiratory and infectious disease drug discovery, including for RSV. By conducting early clinical development and human challenge trials, hVIVO provides pharma clients with reliable RSV testing environments. The company’s work, including laboratory services under hLAB and field trial recruitment via FluCamp, reinforces RSV diagnostic research and positions human challenge models as vital tools in pipeline validation.

RSV Diagnostics Market Share

Hospitals to Lead the Segmentation by End User

The hospitals segment is expected to hold the largest market share, accounting for over 41% during the historical period. This dominance is driven by hospitals’ critical role in managing high-risk RSV cases, especially among infants and the elderly. Their reliance on advanced diagnostic tools, including molecular and immunoassay-based tests, ensures timely interventions and supports accurate clinical decisions. Additionally, high patient inflow and the need for rapid testing contribute to hospitals’ sustained leadership in RSV diagnostics adoption.

RSV Diagnostics Market Analysis by Region

North America is expected to dominate the market due to the extensive adoption of multiplex molecular platforms and strong CDC-led surveillance programs supporting early RSV detection. It accounted for the largest revenue share in the market, capturing approximately 41 % of the total market value. High testing rates during peak seasons, particularly among pediatric and elderly populations, contribute to this lead. Europe follows, driven by government-supported diagnostic reimbursement schemes and the regional launch of high-throughput RSV detection systems like Roche’s cobas® and Panther Fusion. These factors collectively reinforce diagnostic accessibility and lab integration across both regions.

RSV Diagnostics Market: Competitive Landscape and Leading Players

The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

BD (Becton, Dickinson, and Company)

Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD is a global medical technology company offering diagnostic systems, medical devices, and laboratory equipment. In the RSV diagnostics market, BD provides rapid antigen tests such as the BD Veritor™ Plus System, which delivers results for RSV and other respiratory pathogens within minutes. These point-of-care solutions support accurate, timely diagnosis in clinical settings and are widely adopted across hospitals, urgent care centers, and physician offices.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific, established in 2006 and based in Waltham, Massachusetts, is a global leader in scientific research services and diagnostics. Its portfolio in the RSV diagnostics market includes advanced molecular diagnostic tools such as TaqPath™ multiplex real-time PCR assays and Applied Biosystems platforms. These high-sensitivity solutions enable the simultaneous detection of RSV, influenza, and SARS-CoV-2, supporting accurate differential diagnosis in clinical laboratories worldwide, particularly during peak respiratory seasons.

Bio-Rad Laboratories, Inc.

Founded in 1952 and headquartered in Hercules, California, Bio-Rad Laboratories specializes in life science research and clinical diagnostics. In the RSV diagnostics segment, Bio-Rad offers immunoassays and PCR-based testing tools through its respiratory pathogen panels, which allow simultaneous detection of multiple viruses, including RSV. These diagnostics cater to both research and clinical laboratories, enhancing surveillance and testing efficiency during viral outbreaks. The company is known for its precision instruments and reagent systems in infectious disease diagnostics.

F. Hoffmann-La Roche Ltd.

Headquartered in Basel, Switzerland, and established in 1896, F. Hoffmann-La Roche Ltd. is a global pharmaceutical and diagnostics company. Its presence in the RSV diagnostics market is marked by the cobas® LIAT and cobas® 6800/8800 systems, offering rapid molecular testing with high throughput. These systems support multiplex detection of RSV, influenza, and COVID-19, with results available in under 20 minutes for certain assays. Roche’s innovations are widely implemented in hospitals and centralized laboratories across global markets.

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other players in the market include BIOMÉRIEUX, DiaSorin S.p.A., Coris BioConcept, Quest Diagnostics Incorporated, Cepheid (Danaher Corporation), and Johnson & Johnson MedTech.

Global RSV Diagnostics Market Segmentation

"RSV Diagnostics Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:

Market Breakup by Offerings

  • Kits and Assays
  • Instruments

Market Breakup by Method

  • Molecular Diagnostic Testing
  • Rapid Antigen Detection Testing (RADTs)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Immunofluorescence Assay Testing
    • Other Rapid Antigen Detection Testing
      • Chromatographic Immunoassays
      • Optical Immunoassays
    • Others

Market Breakup by End User

  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Others

Market Breakup by Region

  • North America
  • Europe 
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Key Questions Answered in the Global RSV Diagnostics Market 

  • What was the global RSV diagnostics market value in 2024? 
  • What is the global RSV diagnostics market forecast outlook for 2025-2034? 
  • What is the market breakup based on offerings?
  • What is the market segmentation based on methods?
  • What is market segmentation based on the end user?
  • What are the major factors aiding the global RSV diagnostics market demand? 
  • How has the market performed so far, and how is it anticipated to perform in the coming years? 
  • What are the market's major drivers, opportunities, and restraints? 
  • What are the major global RSV diagnostics market trends? 
  • Which offerings will lead the market segment? 
  • Which method will lead the market segment? 
  • Which end user will lead the market segment? 
  • Who are the key players involved in the global RSV diagnostics market? 
  • What are the current unmet needs and challenges in the market? 
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping market dynamics? 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The global RSV diagnostics market attained a value of nearly USD 1028.55 Million in 2024.

The market is projected to grow at a CAGR of 10.20% in the forecast period of 2025-2034.

The market is estimated to witness a healthy growth in the forecast period of 2025-2034 to reach about USD 2716.70 Million by 2034.

The market is being driven by the rising prevalence of RSV disorder, especially amongst children below the age of two and the resultant requirement for an effective diagnostic solution.

Improvements in diagnostics technology and robust investments into the research and development (R&D) activities are expected to aid the market growth in the coming years.

The major regional markets for RSV diagnostics are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

The major products of RSV diagnostics are direct fluorescent antibody (DFA) method, rapid antigen diagnostic test  (RADT), molecular diagnostics, chromatographic immunoassay, diagnostic imaging, gel microdroplets, and flow cytometry, among others.

The major end-uses of RSV diagnostics are hospitals, laboratory, clinics, and homecare.

The major players in the industry are Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, bioMérieux SA, and DiaSorin Molecular LLC, among others.

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2024
Historical Period 2018-2024
Forecast Period 2025-2034
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Offerings
  • Method
  • End User
  • Region
Breakup by Offerings
  • Kits and Assays
  • Instruments
Breakup by Method
  • Molecular Diagnostic Testing
  • Rapid Antigen Detection Testing (RADTs)
Breakup by End User
  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • BD (Becton, Dickinson, and Company)
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • BIOMERIEUX
  • DiaSorin S.p .A.
  • Coris BioConcept
  • Quest Diagnostics Incorporated
  • Cepheid (Danaher Corporation)
  • Johnson & Johnson MedTech

Single User License

10 % Off

USD

5,499

4,949

Datasheet

10 % Off

USD

3,299

2,969

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

Single User License

One User

USD 5,499

USD 4,949

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us